Quantum Genomics: Publication of 2024 annual accounts and strategic developments

Quantum Genomics, listed on Euronext Growth, has published its financial results for 2024, showing zero revenue and a net loss of €8.9 million. Facing financial difficulties, the company saw its shareholders' equity fall from €436,664 in 2023 to -€2,455,941 in 2024. Its cash position stands at €301,018, insufficient to ensure continued operations beyond four months without additional fundraising.

At the same time, the company announced a change in its listing sponsor, moving from Allegra Finance to EuroLand Corporate. Trading in its shares has been suspended since October 2024 due to a proposed reverse acquisition not yet approved by Euronext. Quantum Genomics hopes to resume trading in the future, with merger plans underway, although there is no set timeline.